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SUMMARY – The use of routine blood tests has recently been shown to be promising in deter-
mining disease-free and overall survival in patients with various malignancies, and also in gyneco-
logic malignancies. The aim of this study was to evaluate whether salivary and serum CA125 levels 
correlate and whether salivary and serum CA125, C-reactive protein and routine blood tests might 
serve as a prognostic factor in malignant ovarian tumors, and whether they might differentiate be-
tween benign and malignant ovarian tumors. A total of 98 women were included (48 with benign 
ovarian tumors and 50 with malignant ovarian tumors), in whom routine blood tests were made and 
salivary and serum CA125 levels were determined by use of ELISA. Increase in serum CA125 and 
amylase decreased overall survival, whereas increase in salivary CA125, potassium levels and hemoglo-
bin increased overall survival. Significant correlation of serum CA125 and C-reactive protein was 
found in the group with malignant tumors. In conclusion, significant increase in the levels of serum 
CA125 and amylase correlated with decreased survival, whereas increased salivary CA125, hemoglo-
bin and potassium levels significantly correlated with increased survival.
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Introduction
Recent publications highlight a greater role of 
common blood tests in patients with various cancers 
than previously assumed. Malignant tumors are often 
accompanied by a higher risk of hematologic abnor-
malities. Recent studies have shown that the presence 
of systemic inflammation correlates with poorer dis-
ease-free and overall survival in cancer patients1-3. 
Anemia, hemoglobinemia, thrombocytosis and leuko-
cytosis are thought to be adverse prognostic factors in 
various malignancies. Thrombocytosis, leukocytosis 
and anemia have been demonstrated to be indepen-
dent poor prognostic factors in ovarian, endometrial 
and uterine serous papillary carcinoma. It is known 
that over 20% of ovarian cancer patients have preop-
erative thrombocytosis or hyperfibrinogenemia4. Fur-
thermore, we assumed that salivary and serum CA125 
levels might differentiate benign from malignant ovar-
ian masses as salivary samples are easier to collect, 
cheaper and noninvasive.
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Materials and Methods
This study was approved by the Ethics Committee 
of the School of Dental Medicine, University of Za-
greb, Zagreb, Croatia. All participants signed informed 
consent according to Helsinki II. A total of 98 women 
treated at Sestre milosrdnice University Hospital Cen-
tre were included in the study. Of them, 48 had benign 
ovarian tumors and 50 malignant ovarian tumors. In 
all patients, saliva and serum were collected for deter-
mination of CA125. Routine blood tests were made in 
all patients.
Saliva was collected according to Wu Wang et al.5 
over five minutes at 8-10 AM into calibrated test 
tubes, while participants were sitting. Saliva samples 
were delivered to laboratory within 30 minutes after 
sampling and immediately frozen-stored at -20 °C. 
On the day of assay, the samples were thawed, vortexed 
and centrifuged for 15 minutes at 396 xg on a Rotina 
35R centrifuge (Hettich, Kirchlengern, Germany). Pe-
ripheral blood samples were collected by venipuncture 
in two Vaccuete® red cap serum tubes with clot activa-
tor (Greiner Bio-One, Kremsmünster, Austria). Blood 
for serum testing was centrifuged for 10 minutes at 4 
°C and 2150 g on a benchtop centrifuge.
From one tube, C-reactive protein (CRP), calcium 
and amylase were instantly determined in sera. CRP 
was determined by immunoturbidimetry, calcium and 
amylase by photometry, all on an Architect c8000 clin-
ical chemistry analyzer (Abbott, IL, USA). The recom-
mended reference values for CRP, calcium and amy-
lase are: <5 ng/L, 2.10-2.55 mmol/L and 25-125 U/L, 
respectively.
From the other tube, two aliquots (2x0.5 mL) of 
serum samples were immediately frozen at -20 °C un-
til analysis of tumor markers. At the time of determi-
nation, aliquots were defrosted by leaving them at 
room temperature until liquid state.
The CA125 tumor marker was measured in serum 
and in saliva on an Immulite 1000 automatic immuno-
chemistry analyzer (Siemens Healthcare Diagnostics, 
Erlangen, Germany) by the chemiluminescent enzyme 
immunometric method using original Siemens re-
agents and adjustors according to the manufacturers’ 
instructions. The calibration range for CA125 is 500 
kIU/L with analytical sensitivity 0.2 kIU/L. The rec-
ommended cut-off value for serum samples in women 
is 18 kIU/L (95%).
Statistical analysis was performed using the STA-
TISTICA version 12 (StatSoft, Inc., Tulsa, OK, USA) 
software and MedCalc version 19 (MedCalc Software, 
Ostend, Belgium; https://www.medcalc.org; 2019). 
Categorical variables were expressed as number and 
percentage (%). Quantitative variables were tested for 
normality of distribution by use of Kolmogorov-
Smirnov test and expressed as arithmetic mean (M) 
and standard deviation (SD) or as median or inter-
quartile range (IQR), depending on the type of distri-
bution. Difference between the groups for quantitative 
variables was tested with Mann-Whitney U-test. The 
correlation between two tested CA125 measurements 
(serum and saliva) was tested with Spearman correla-
tion analysis, concordance test and Bland-Altman 
analysis together with graphic presentation. The cor-
relation of salivary and serum CA125 with other vari-
ables in the two groups (benign and malignant) was 
tested with Spearman correlation analysis. ROC anal-
ysis was used for CA125 predictability (serum and sa-
liva) for malignant disease under the curve (AUC) 
with 95% confidence interval (95% CI), sensitivity and 
specificity, positive and negative ratio for diagnosis 
(+LR, -LR) with 95% CI for various borderline values. 
Kaplan-Meier analysis was used for overall survival in 
patients with malignant disease. Overall survival was 
the time from the diagnosis until death. The correla-
tion between overall survival and potential predictors 
(independent variables) was assessed by Cox regres-
sion analysis and the results were expressed as hazard 
ratio and 95% CI. In all analyses, the level of statistical 
significance was set at p<0.05.
Results
The study included 98 women (48 with benign tu-
mors and 50 with malignant tumors) in whom saliva 
and serum were collected for CA125 determination. 
Patient characteristics are shown in Table 1. The group 
with malignant tumors was significantly older than the 
group with benign tumors (59.3±14.5 years vs. 
46.9±16.24 years, p<0.001) and had significantly high-
er salivary CA125 levels (median (IQR), >500 (>500-
>500) vs. >500 (252->500) kIU/L, p=0.017), serum 
CA125 levels (median (IQR), 491.7 (145.7-855.0) vs. 
28.1 (12.1-66.1) kIU/L, p<0.001) and CRP levels 
(median (IQR), 23.1 (7.2-62.6) vs. 3.10 (1.35-4.85) 
mg/L, p<0.001). In addition, patients with malignant 
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tumors had significantly higher leukocyte and platelet 
count (p<0.001 both) and lower hemoglobin level 
(p<0.001). Other parameters were comparable in the 
two patient groups (red blood cell (RBC) count, potas-
sium, sodium, chloride and calcium levels (p>0.05 all) 
and amylase (p=0.537).
There was no significant correlation between sali-
vary and serum CA125 in the whole sample (N=98; 
R=-0.006; p=0.953; Spearman correlation analysis) or 
coincidence of the results (CCC=-0.065; 95% CI=-
0.177-0.049). Bland-Altman analysis revealed signifi-
cant disparity of the results (Fig. 1), where linear de-
pendence (increase) of serum and salivary CA125 was 
noticed in serum.
Analysis of salivary and serum CA125 in patients 
with malignant tumors (n=44) showed the same pat-
tern (R=0.087; p=0.575; Spearman correlation analy-
sis) of incompatibility as in the whole sample, whereas 
in the group with benign tumors (n=47) slight signifi-
cance was obtained which was inversely related to sali-
vary and serum CA125 (R=-0.415; p=0.004; Spear-
man correlation analysis) (Fig. 2). The increase in se-
rum CA125 correlated with decreased salivary CA125.
Tables 2 and 3 show significant correlation be-
tween serum CA125 and age in patients with benign 
and malignant ovarian tumors, i.e. negative correlation 
in patients with benign tumors (R=-0.299, p=0.041) 
and positive correlation in patients with malignant tu-
Table 1. Patient characteristics (N=98)
Variable
Benign tumors Malignant tumors Statistics
 n M±SD* n M±SD* Z p-value
Year of birth 48 [1931-2001] 50 [1935-1992] 3.678 <0.001
Age (yrs) 48 46.9±16.24 50 59.3±14.5 -3.678 <0.001
CA125 saliva 
(kIU/L) 48 >500 (252->500) [9.6->500] 50 >500 (>500->500) [38.4->500] -2.379 0.017
CA125 serum 
(kIU/L) 48 28.1 (12.1-66.1) [4.5->500] 50 491.7 (145.7-855.0) [9.6-10000] -5.590 <0.001
Red blood cells 
(1012/L) 48 4.39±0.46 50 4.25±0.52 1.620 0.105
Hemoglobin (g/L) 48 132±14 50 122±14 3.642 <0.001
Leukocytes (109/L) 47 7.33±2.37 50 9.35±2.63 -4.136 <0.001
Platelets (109/L) 47 240±72 49 333±116 -4.551 <0.001
Potassium (mmol/L) 47 4.2±0.4 50 4.4±0.5 -1.617 0.106
Sodium (mmol/L) 15 140±2.5 29 137±6 1.300 0.194
Chloride (mmol/L) 15 105±2 26 104±4 0.866 0.386
Calcium (mmol/L) 44 2.40±0.11 49 2.37±0.20 1.931 0.053
Amylase (U/L) 47 55±22 48 56.5 (42.0-65.0) [13-1304] -0.618 0.537
C-reactive protein 
(mg/L) 48 3.10 (1.35-4.85) 50 23.1 (7.2-62.6) -6.101 <0.001
*data are presented as arithmetic mean (M) ± standard deviation (SD) or as median (interquartile range) and/or range.
Fig. 1. Bland-Altman plot comparisons of salivary  
and serum CA125.
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mors (R=0.307, p=0.034). In patients with benign tu-
mors, there was significant correlation of salivary 
CA125 with RBC count (R=0.356, p=0.014) and he-
moglobin values (R=0.351, p=0.016). In the group 
with malignant tumors, there was significant correla-
tion between serum CA125 and CRP (R=0.484, 
p<0.001). All these significant correlations were weak. 
All other laboratory measurements yielded no signifi-
cant correlation with salivary and serum CA125 in ei-
ther patient group (Tables 2 and 3).
In order to predict serum CA125 in patients with 
malignant disease, ROC analysis for group compa-
rison was performed and yielded significant differ-
ences by AUC from 0.833 (95% CI, 0.743-0.902, 
z=7.918; p<0.001) with difference criteria of >109 
kIU/L CA125 with 79.17% sensitivity (95% CI, 65.0-
Fig. 2. Scattering of the correlation between salivary  
and serum CA125 in the group of benign tumors  
(n=47; R=-0.415; p=0.004; Spearman correlation 
analysis).
Table 2. Correlation of salivary and serum CA125  
with age and laboratory measurements in the group  
with benign tumors
n R p-value
CA125 saliva/age 47 0.277 0.060
CA125 saliva/red blood cells 47 0.356 0.014
CA125 saliva/hemoglobin 47 0.351 0.016
CA125 saliva/leukocytes 46 0.046 0.761
CA125 saliva/platelets 46 -0.013 0.931
CA125 saliva/potassium 46 0.117 0.441
CA125 saliva/sodium 15 -0.126 0.654
CA125 saliva/chloride 15 0.022 0.937
CA125 saliva/calcium 43 0.062 0.693
CA125 saliva/amylase 46 0.208 0.165
CA125 saliva/C-reactive protein 47 0.097 0.516
CA125 serum/age 47 -0.299 0.041
CA125 serum/red blood cells 47 0.004 0.978
CA125 serum/hemoglobin 47 -0.161 0.279
CA125 serum/leukocytes 46 0.058 0.704
CA125 serum/platelets 46 -0.106 0.483
CA125 serum/potassium 46 0.143 0.344
CA125 serum/sodium 15 -0.151 0.592
CA125 serum/chloride 15 0.073 0.795
CA125 serum/calcium 43 -0.073 0.642
CA125 serum/amylase 46 -0.125 0.407
CA125 serum/C-reactive protein 47 0.240 0.105
Data are expressed as number of participants (n); R = Spearman 
correlation coefficient
Table 3. Correlation of salivary and serum CA125  
with age and laboratory measurements in the group  
with malignant tumors
n R p-value
CA125 saliva/age 44 -0.239 0.118
CA125 saliva/red blood cells 44 0.200 0.193
CA125 saliva/hemoglobin 44 0.153 0.323
CA125 saliva/leukocytes 44 -0.054 0.729
CA125 saliva/platelets 43 0.036 0.817
CA125 saliva/potassium 44 0.006 0.967
CA125 saliva/sodium 24 -0.336 0.109
CA125 saliva/chloride 21 0.034 0.883
CA125 saliva/calcium 43 0.146 0.350
CA125 saliva/amylase 42 -0.104 0.514
CA125 saliva/C-reactive protein 44 -0.079 0.609
CA125 serum/age 48 0.307 0.034
CA125 serum/red blood cells 48 -0.034 0.819
CA125 serum/hemoglobin 48 -0.139 0.347
CA125 serum/leukocytes 48 0.205 0.162
CA125 serum/platelets 47 0.202 0.173
CA125 serum/potassium 48 0.097 0.513
CA125 serum/sodium 27 -0.163 0.416
CA125 serum/chloride 24 0.172 0.423
CA125 serum/calcium 47 -0.079 0.599
CA125 serum/amylase 46 0.122 0.421
CA125 serum/C-reactive protein 48 0.484 0.000
Data are expressed as number of participants (n); R = Spearman 
correlation coefficient
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89.5%) and 80.85% specificity (95% CI, 66.7-90.9%) 
(Fig. 3).
In order to determine salivary CA125 predictabil-
ity in malignant tumors, ROC analysis was performed 
by comparison of the groups and significant differ-
ences were determined by AUC of 0.645 (95% CI, 
0.538-0.743, z=2.94; p=0.003) (Fig. 4).
Predictability of serum CA125 was significantly 
better when compared to salivary CA125 (p<0.05), 
with significantly better specificity (p<0.05).
Overall survival analysis showed that median over-
all survival in patients with malignant disease was 21.9 
months (IQR 3.39, unknown) with 95% CI of 11.6-
44.7 months. Cox regression analysis showed a model 
that significantly predicted survival (χ2-=32.305, df=5; 
p<0.001). Significantly independent predictive vari-
ables for overall survival were CA125 in serum and 
saliva, amylase, hemoglobin and potassium (Table 4). 
Increase in serum CA125 by every kIU/L decreased 
overall survival by 0.1% (HR 1.001, p=0.013). Increase 
in salivary CA125 by every kIU/L increased overall 
survival by 0.7% (HR 0.993, p=0.002). Increase in 
amylase by every U/L decreased overall survival by 
0.9% (HR 1.009, p=0.013). Increase in hemoglobin by 
every g/L increased overall survival by 4% (HR 0.960, 
p=0.044). Increase in potassium levels by every 
Fig. 3. ROC curve of sensitivity/specificity for serum 
CA125.
Fig. 4. ROC curve of sensitivity/specificity for salivary 
CA125.
Table 4. Prediction variables that significantly correlated with overall survival in patients with malignant tumors 
(N=50)
Covariable b SE Wald p-value Exp(b) 95% CI for Exp(b)
CA125 serum (kIU/L) 0.00038 0.0002 6.177 0.013 1.001 1.0001 to 1.0007
CA125 saliva (kIU/L) -0.00737 0.0024 9.571 0.002 0.993 0.9880 to 0.9973
Amylase (U/L) 0.00847 0.0034 6.094 0.014 1.009 1.0017 to 1.0153
Hemoglobin (g/L) -0.04096 0.0203 4.059 0.044 0.960 0.9224 to 0.9989
Potassium (mmol/L) -1.13840 0.4754 5.734 0.017 0.320 0.1262 to 0.8133
b = regression coefficient; SE = standard error; Wald = results of Wald statistics; Exp(b) = hazard ratio (HR); 95% CI for Exp(b) = 95% 
confidence interval for HR
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mmol/L increased overall survival by 78% (HR 0.320, 
p=0.017).
Discussion
Younes et al.4 found that leukocytosis and neutro-
philia significantly correlated with aggressive tumor 
biology and may predict a lower 5-year survival. Their 
study was performed in 56 women and the results 
showed that leukocyte and neutrophil levels were ad-
versely associated with survival. Of 15 patients with 
leukocytosis >10000/μL, 67% were dead at the end of 
follow up, and of 27 patients with neutrophils above 
65%, 14 (52%) were dead at the end of follow up. These 
findings are not in concordance with ours where leu-
kocytosis did not correlate with shorter overall sur-
vival. However, in our study, leukocytosis was more 
prevalent in patients with malignant in comparison to 
patients with benign ovarian masses. Feng et al.6 ana-
lyzed 875 patients and report that both preoperative 
thrombocytosis and hyperfibrinogenemia were associ-
ated with an advanced Fédération Internationale de 
Gynécologie et d’Obstétrique (FIGO) stage of ovarian 
cancer, elevated CA125 level, more extensive ascites, 
more extensive residual disease, and chemosensitivity. 
However, thrombocytosis was not found to be a po-
tential predictor of disease-free and overall survival, 
which is in concordance with the results of our study. 
Słabuszewska-Jóźwiak et al.7 reviewed 349 patients 
with ovarian tumor and defined thrombocytopenia 
when platelet count was below 150 G/L and thrombo-
cythemia when platelets were at 350 G/L and higher. 
Thrombocytosis often coincides with ascites and cyto-
reduction decreases platelet count. Thrombocytosis 
was more frequently found in high grade tumors and 
in stage III and IV cancers. Patients with co-occurring 
thrombocytosis were found to have shorter survival 
periods and shorter disease-free period. This finding 
was also contradictory to our finding as we found no 
differences regarding thrombocytosis and overall sur-
vival in our patients with malignant ovarian tumors. 
Yilmaz et al.8 found serum CA125 levels to be in-
creased only in one-third of patients with 1A FIGO 
stage of borderline ovarian tumors, while Seckin et al.9 
found that CA19-9, neutrophil/lymphocyte ratio 
(NLR) and CA125 were significant predictors of ma-
lignancy in patients who had an intraoperative frozen 
section diagnosis of borderline mucinous ovarian tu-
mors. Patient age, menopausal status, hemoglobin, 
platelet and lymphocyte counts were not different be-
tween the groups. However, white blood cell and neu-
trophil counts, NLR, CA125 and CA19-9 were sig-
nificantly higher in malignant cases. This finding is 
partially in concordance with our results as we also 
found increased white blood cell count and CA125 in 
patients with malignant tumors. Utsumi et al.10 re-
viewed 77 charts of terminally ill patients with ovarian 
cancer and concluded that poorer performance status, 
elevated white blood cell count and higher CRP value 
significantly correlated with shorter survival. This is 
partially in concordance with the results of our study, 
which revealed significant correlation of higher CRP 
and shorter overall survival. Chen et al.11 report that 
preoperative anemia, leukocytosis or thrombocytosis 
in epithelial ovarian cancer (EOC) patients is closely 
associated with a more malignant disease phenotype 
and poorer prognosis. Significantly, thrombocytosis 
may independently predict disease-specific survival in 
EOC patients. Their results were based on 816 Chi-
nese women. This finding is contrary to ours, as we 
found no correlation between thrombocytosis and 
overall survival in patients with malignant ovarian tu-
mors. So et al.12 analyzed 155 women, 23 (14.8%) of 
them with leukocytosis and 132 (85.2%) without leu-
kocytosis. Recurrence-free survival and overall survival 
were significantly shorter in women with leukocytosis 
than in those without leukocytosis. The mortality rate 
was also higher among women with leukocytosis. The 
same authors12 conclude that preoperative leukocytosis 
might be an independent prognostic factor for recur-
rence-free survival and overall survival in women with 
EOC. This was not confirmed in our study as preop-
erative leukocytosis did not correlate with overall sur-
vival in patients with malignant ovarian tumors. Co-
hen et al.13 reviewed 107 women with invasive EOC 
and thrombocytosis was determined as platelet count 
≥350×109/L and optimal resection at secondary cyto-
reductive surgery as microscopic residual disease. The 
same authors13 report that elevated platelet count at 
the time of secondary cytoreductive surgery is associ-
ated with suboptimal resection and shortened overall 
survival. Furthermore, Ma et al.14 also report that 
thrombocytosis accompanied by increasing platelet 
aggregation rates is associated with a more aggressive 
tumor biology and negative prognostic factor for over-
all survival in EOC patients. This finding was not con-
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firmed in our study. Thrombocytosis finding was dif-
ferent in patients with benign and malignant ovarian 
tumors; however, it was not correlated with shorter 
overall survival in patients with malignant ovarian 
masses. Nomelini et al.15 report that CA125, CA15.3, 
hemoglobin, and platelets might be indicators of prog-
nosis in patients with ovarian cancer. This is partially 
consistent with our results as we also found serum 
CA125 and hemoglobin to be independent predictors 
of overall survival; however, platelets were not inde-
pendent predictors of overall survival in patients with 
ovarian cancer. Contrary to these findings, Younes et 
al.4 could not confirm that hemoglobin values signifi-
cantly correlated with 5-year survival. Furthermore, 
Altman et al.16 suggested that hemoglobin levels were 
weakly associated with recurrence-free survival and 
overall survival.
In the literature published to date, there are scarce 
data on salivary, serum and urinary CA125 levels in 
patients with these cancers. Geng et al.17 report on in-
creased salivary CA125 levels in patients with oral 
cancer when compared to those with benign cancers 
and controls. Agha-Hosseini et al.18 report that sali-
vary and serum CA125 were significantly increased in 
patients with untreated breast cancer as compared to 
patients with treated breast cancer and controls. Tay 
and Chua19 report that serum and urinary CA125 lev-
els were significantly increased in patients with malig-
nant ovarian cancer when compared to those with be-
nign ovarian tumors. However, no significant differ-
ences were found regarding salivary CA125 levels in 
these groups, which is contrary to our findings. Chen 
and Li20 report that salivary CA125 had better diag-
nostic value when compared to serum CA125 in pa-
tients with ovarian cancer. The results of this study 
showed that patients with malignant tumors had sig-
nificantly higher salivary and serum CA125 levels 
when compared to patients with benign tumors. How-
ever, there was no significant correlation between sali-
vary and serum CA125 in the whole sample.
The results of this study showed that patients with 
malignant tumors were significantly older than those 
with benign tumors, and had significantly higher sali-
vary and serum CA125 and CRP levels. Patients with 
malignant tumors also had significantly higher leuko-
cyte and platelet counts, and lower hemoglobin level. 
Significantly independent predictive variables for 
overall survival were serum and salivary CA125, amy-
lase, hemoglobin and potassium. In patients with ma-
lignant tumors, there was a significant correlation of 
serum CA125 and CRP. Significantly increased levels 
of serum CA125 and amylase correlated with de-
creased survival, whereas increased salivary CA125, 
hemoglobin and potassium levels significantly corre-
lated with increased survival.
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Sažetak
ULOGA SALIVARNOG I SERUMSKOG CA125 I RUTINSKIH NALAZA KRVI  
KOD BOLESNICA SA ZLOĆUDNIM TUMORIMA JAJNIKA
A. Vuković, K. Kuna, B. Lončar Brzak, V. Vučičević Boras, R. Šeparović, M. Šekerija, L. Šumilin i V. Vidranski
U posljednje vrijeme pokazalo se da su rutinski testovi krvi obećavajući u određivanju razdoblja bez bolesti i ukupnog 
preživljenja bolesnika s različitim zloćudnim bolestima, uključujući i ginekološke malignitete. Cilj ovoga istraživanja bio je 
procijeniti koreliraju li razine CA125 u slini i serumu te mogu li CA125, C-reaktivni protein u slini i serumu i rutinske pre-
trage krvi poslužiti kao prognostički čimbenik u malignim tumorima jajnika te mogu li razlikovati dobroćudne i zloćudne 
tumore jajnika. U istraživanje je uključeno 98 žena (48 s dobroćudnim tumorima jajnika i 50 sa zloćudnim tumorima jajnika), 
kod kojih su izvedene rutinske analize krvi i razine CA125 u slini i serumu primjenom testa ELISA. Povećanje serumskog 
CA125 i amilaze smanjuje ukupno preživljavanje, dok povećanje salivarnog CA125, razine kalija i hemoglobina povećava 
ukupno preživljavanje. U skupini sa zloćudnim tumorima zabilježena je značajna korelacija serumskog CA125 s C-reaktiv-
nim proteinom. Može se zaključiti da su značajno povišene razine CA125 i amilaze u serumu bile u korelaciji sa smanjenim 
preživljenjem, dok je povišena razina CA125, hemoglobina i kalija značajno povezana s povećanim preživljenjem.
Ključne riječi: Maligniteti; CA125 antigen; Krvne pretrage
